Kolltan Pharmaceuticals Licenses Novel anti-KIT Antibodies and Related ... Business Wire (press release) BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the ... |
